A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

NCT04992065 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

267

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerotic Cardiovascular Disease

Interventions

DRUG: NNC0385-0434 A 15 mg
DRUG: NNC0385-0434 A 40 mg
OTHER: Placebo I A (for NNC0385-0434 A 15 mg)
DRUG: NNC0385-0434 A 100 mg
OTHER: Placebo I A (for NNC0385-0434 A 40 mg)
OTHER: Placebo II A (for NNC0385-0434 A 100 mg)
DRUG: Evolocumab 140 mg/mL, Repatha®

Sponsor

Novo Nordisk A/S